ecte8kamay282013.htm

Delaware	000-23017	41-1649949
(State or other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

8Penn Center 1628 JFK Blvd., Suite 300 Philadelphia, PA		19103
(Address of principal executive offices)		(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Echo Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 on Form 8-K/A to the Company’s Current Report on Form 8-K filed on May 23, 2013 (the “Form 8-K”) to amend and restate the Form 8-K in its entirety to correct an inadvertent error in voting results. The results reflected in this Form 8-K/A are based on a vote tabulation report certified by Broadridge Tabulation Services.

At the Company’s 2013 Annual Meeting of Stockholders held on May 22, 2013, the following matters were acted upon by the Company’s stockholders:

1.	The election of Vincent D. Enright, a Class II director, to the Company’s Board of Directors for a term of three years and the election of Robert F. Doman, a Class III director, to the Company’s Board of Directors for a term of one year;

The approval of an amendment to the Company's Certificate of Incorporation, as amended, to effect a reverse stock split by a ratio of not less than 1-for-2 and not more than 1-for-10 at any time prior to December 31, 2013, with the exact ratio to be set within this range by the Company’s Board of Directors in its sole discretion;

3.	The approval of an amendment to the Company's 2008 Equity Incentive Plan to fix the aggregate number of shares of common stock subject to the 2008 Plan at 10,000,000 shares subject to the approval of the reverse stock split and after giving effect to the reverse stock split;

4.	The approval of an amendment to the Company's 2008 Equity Incentive Plan to fix the limitation on awards of stock options during any twelve-month period to any one participant at 425,000 shares, subject to the approval of the reverse stock split and after giving effect to the reverse stock split;

5.	The ratification of the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013.

The results of voting on each of the matters presented to stockholders at the Annual Meeting are set forth below:

1.	Election of Vincent D. Enright, a Class II director, to the Company’s Board of Directors for a term of three years and the election of Robert F. Doman, a Class III director, to the Company’s Board of Directors for a term of one year:

	FOR		AGAINST / WITHHELD		ABSTENTIONS		BROKER NON-VOTES
Vincent D. Enright		22,889,879		1,105,223		—		21,167,306
Robert F. Doman		22,885,577		1,109,525		—		21,167,306

Approval of an amendment to the Company's Certificate of Incorporation, as amended, to effect a reverse stock split by a ratio of not less than 1-for-2 and not more than 1-for-10 at any time prior to December 31, 2013, with the exact ratio to be set within this range by the Company’s Board of Directors in its sole discretion:

FOR			AGAINST / WITHHELD			ABSTENTIONS			BROKER NON-VOTES
38,342,701			5,260,030			1,559,677			—

3.	Approval of an amendment to the Company's 2008 Equity Incentive Plan to fix the aggregate number of shares of common stock subject to the 2008 Plan at 10,000,000 shares subject to the approval of the reverse stock split and after giving effect to the reverse stock split:

FOR			AGAINST / WITHHELD			ABSTENTIONS			BROKER NON-VOTES
18,464,850			5,064,006			466,246			21,167,306

4.	Approval of an amendment to the Company's 2008 Equity Incentive Plan to fix the limitation on awards of stock options during any twelve-month period to any one participant at 425,000 shares, subject to the approval of the reverse stock split and after giving effect to the reverse stock split:

FOR			AGAINST / WITHHELD			ABSTENTIONS			BROKER NON-VOTES
18,574,257			4,980,114			440,731			21,167,306

5.	Ratification of the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013:

FOR			AGAINST / WITHHELD			ABSTENTIONS			BROKER NON-VOTES
43,309,683			1,197,673			655,052			—

The Exhibits listed in the Exhibit Index immediately preceding such Exhibits are filed with or incorporated by reference in this report.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ECHO THERAPEUTICS, INC.
Dated: May 28, 2013	By: /s/ Patrick T. Mooney
	Patrick T. Mooney
	President and Chief Executive Officer

Exhibit No.		Description
99.1		Press Release issued by the Company on May 23, 2013.